Knowledge products overview

10th February 2026

Drug Compatibility Checker

For February, published data has been amended for 109 drugs from ASHP’s Injectable Drug Information. 18 new clinical practice reports from Palliative Care Formulary’s Syringe Driver Database have been added.

10th February 2026

Palliative Care Formulary

This update contains 1 new monograph and 1 revised monograph.

The following monograph is new: Vitamin B12 substances.

The following monograph has been fully revised: Drugs for hyperkalaemia
(formerly Potassium).

10th February 2026

Stockley’s Interactions Checker

For February, 469 new interactions have been added, and 1032 existing interactions have been updated.

10th February 2026

Pharmaceutical Excipients

This update contains 5 updated monographs.

Selective revisions: Microcrystalline cellulose, Glycerol, Sodium Bicarbonate, Magnesium Stearate, Propylene Glycol

10th February 2026

Stockley’s Drug Interactions

This update of Stockley’s Drug Interactions consists of 41 new monographs and 134 updated monographs, including updates to the content on activated factor X inhibitors and esketamine. The aminoglycosides monographs have been revalidated and updated, and new drugs have been added including the hypoxia-inducible factor prolyl hydroxylase inhibitors, roxadustat and vadadustat.

10th February 2026

British National Formulary

This update contains 12 significant changes, 3 dose changes and 2 new monographs.

Significant Changes:

• Birch bark extract: name change to birch bark extracts.
• Diarrhoea (acute): updated guidance on the use of antibacterial drugs for acute diarrhoea.
• Epilepsy: updated guidance on management.
• Givinostat: new important safety information.
• Mesalazine and idiopathic intracranial hypertension [MHRA/CHM advice].
• Penicillamine: harm from incorrect recording of a penicillin allergy as a penicillamine allergy [National Patient Safety Alert advice].
• Penicillins: harm from incorrect recording of a penicillin allergy as a penicillamine allergy [National Patient Safety Alert advice] (advice in all penicillins; see example in amoxicillin).
• Respiratory system infections, antibacterial therapy: updated guidance on community-acquired pneumonia.
• Respiratory system infections, antibacterial therapy: updated guidance on hospital-acquired pneumonia.
• Semaglutide (Rybelsus®): transition to new formulation and risk of medication error [MHRA/CHM advice].
• Vaccination, general principles: updated guidance on vaccination in pregnancy.
• Vutrisiran: new indications and dose for treatment of wild-type and hereditary transthyretin amyloidosis in patients with cardiomyopathy.

Dose Changes:

• Amoxicillin [update to age ranges and duration of treatment for community-acquired pneumonia in children].
• Clarithromycin [update to age ranges and duration of treatment for community-acquired pneumonia in children].
• Erythromycin [update to age ranges and duration of treatment for community-acquired pneumonia in children].

New Monographs:

• Beyonttra® [acoramidis] for Wild-type transthyretin amyloidosis in patients with cardiomyopathy (wtATTR-CM) (initiated under specialist supervision); Hereditary transthyretin amyloidosis in patients with cardiomyopathy (hATTR-CM) (initiated under specialist supervision).
• Voranigo® [vorasidenib] for Astrocytoma; Oligodendroglioma.